A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

October 13, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

October 15, 2022

Conditions
Hyperphosphatemia
Interventions
DRUG

VS-505

4 dosages of experimental drug

DRUG

Sevelamer Carbonate

Active Comparator

Trial Locations (23)

Unknown

Peking University People's Hospital, Beijing

Peking University Third Hospital, Beijing

Zhongshan Hospital Xiamen University, Xiamen

Affiliated Hospital of Guilin Medical University, Guilin

The Third Hospital of Hebei Medical University, Shijiazhuang

The Second Affiliated Hospital of Xingtai Medical College, Xingtai

Renmin Hospital of Wuhan University, Wuhan

The Second People's Hospital of Changzhou, Changzhou

The Second Affiliated Hospital of Nanjing Medical University, Nanjing

Affiliated Hospital of Nantong University, Nantong

Wuxi People's Hospital, Wuxi

Northern Jiangsu People's Hospital, Yangzhou

Jilin Province People's Hospital, Changchun

The Second Hospital of Jilin University, Changchun

Dalina Municipal Central Hospital, Dalian

The First Hospital of Dalian Medical University, Dalian

The Second Hospital of Dalian Medical University, Dalian

Shanghai General Hospital, Shanghai

Shanghai Tenth People's Hospital, Shanghai

Xinhua Hospital Affiliated to Shanghai Jiao Tong Universiity School of Medcine, Shanghai

The Second Hospital of Shanxi Medical University, Taiyuan

Tianjin People's Hospital, Tianjin

Zhejiang Provincial People's Hospital, Hangzhou

All Listed Sponsors
lead

Shanghai Alebund Pharmaceuticals Limited

INDUSTRY

NCT04551300 - A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients | Biotech Hunter | Biotech Hunter